With Dr. Carl Peter Thürmel, Vice-chairman of the Advisory Board of the Röchling Group in attendance, the new building was ceremoniously opened by Röchling Group and Medical division CEO Professor Hanns-Peter Knaebel, who transferred the building to Joachim Lehmann, BU Director Medical Europe, and to Alexander Stauch, Managing Director BU Medical Europe.
The Röchling Group is investing EUR 35 million in its Neuhaus am Rennweg site, creating around 70 new, modern jobs for specialists and managerial staff in the process. The production capacities of Röchling Medical Neuhaus GmbH & Co. KG are being increased significantly and the market position of the specialist in manufacturing primary packaging for the pharmaceutical and diagnostics industries is being strengthened considerably.
Signs point to growth
The Röchling Group launched the Medical division in 2016, bolstering its two existing divisions, Industrial and Automotive, and setting the scene for a clear strategic focus on developing and manufacturing high-quality plastic products for pharmaceutical, diagnostics, surgical and life sciences applications. Röchling Medical develops innovative solutions across these sectors, strengthening its leading market position around the world. Through intensive marketing efforts, this has spurred Röchling Medical on to win major projects necessitating the expansion of production capacity in the area of co-extrusion blow molding.
At its site in Neuhaus am Rennweg, a new production building has been built that houses the manufacture of primary packaging for pharmaceutical products under ultra-modern Class GMP C (approx. 1,100 m²) and Class GMP D (approx. 500 m²) clean room conditions.
